Head and neck cancer: pathogenesis and targeted therapy

Abstract

Head and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, and drug resistance. The occurrence of HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, and complex genetic and epigenetic predisposition. Currently, surgery and radiotherapy are the standard treatments for most patients with early-stage HNC. For recurrent or metastatic (R/M) HNC, the first-line treatment is platinum-based chemotherapy combined with the antiepidermal growth factor receptor drug cetuximab, when resurgery and radiation therapy are not an option. However, curing HNC remains challenging, especially in cases with metastasis. In this review, we summarize the pathogenesis of HNC, including genetic and epigenetic changes, abnormal signaling pathways, and immune regulation mechanisms, along with all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene therapy, epigenetic modifications, and combination therapies. Recent preclinical and clinical studies that may offer therapeutic strategies for future research on HNC are also discussed. Additionally, new targets and treatment methods, including antibody–drug conjugates, photodynamic therapy, radionuclide therapy, and mRNA vaccines, have shown promising results in clinical trials, offering new prospects for the treatment of HNC.

Keywords

clinical strategies / HNC / immunotherapy / pathogenesis / targeted therapy

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2] Li QF, Tie Y, Alu A, Ma XL, Shi HS. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Tar. 2023; 8(1): 31.

[3] Chow LQM, Longo DL. Head and neck cancer. New Engl J Med. 2020; 382(1): 60-72.

[4] Lim I, Tan J, Alam A, et al. Epigenetics in the diagnosis and prognosis of head and neck cancer: a systematic review. J Oral Pathol Med. 2024; 53(2): 90-106.

[5] Ringash J, Bernstein LJ, Devins G, et al. Head and neck cancer survivorship: learning the needs, meeting the needs. Semin Radiat Oncol. 2018; 28(1): 64-74.

[6] Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet North Am Ed. 2021; 398(10318): 2289-2299.

[7] Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer (vol 377, pg 513, 2017). New Engl J Med. 2018; 378(10): 973-973.

[8] Xu M, Yao YY, Chen H, et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat Genet. 2019; 51(7): 1131-1136.

[9] Ruffin AT, Li HSY, Vujanovic L, et al. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023; 23(3): 173-188.

[10] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48.

[11] Budach V, Tinhofer I. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. Lancet Oncol. 2019; 20(6): E313-E326.

[12] Bozec A, Poissonnet G, Dassonville O, Culié D. Current therapeutic strategies for patients with hypopharyngeal carcinoma: oncologic and functional outcomes. J Clin Med. 2023; 12(3): 1237.

[13] Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2018; 24(1): 6-13.

[14] Bhat GR, Hyole RG, Li J. Head and neck cancer: current challenges and future perspectives. Adv Cancer Res. 2021; 152: 67-102.

[15] Alfouzan AF. Radiation therapy in head and neck cancer. Saudi Med J. 2021; 42(3): 247-254.

[16] Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J. 2020; 38(2): 84-92.

[17] Longton E, Schmit K, Fransolet M, Clement F, Michiels C. Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma. Front Oncol. 2018; 8: 432.

[18] Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391): 1853-1865.

[19] Constantin M, Chifiriuc MC, Bleotu C, et al. Molecular pathways and targeted therapies in head and neck cancers pathogenesis. Front Oncol. 2024; 14: 1373821.

[20] Lillo S, Mirandola A, Vai A, et al. Current status and future directions of proton therapy for head and neck carcinoma. Cancers. 2024; 16(11).

[21] Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Brit J Cancer. 2020; 122(3): 306-314.

[22] Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536): 576-582.

[23] Pinkiewicz M, Dorobisz K, Zatoński T. Human papillomavirus-associated head and neck cancers. where are we now? A systematic review. Cancer Manag Res. 2022; 14: 3313-3324.

[24] Akagi K, Li J, Broutian TR, et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014; 24(2): 185-199.

[25] Constantin M, Chifiriuc MC, Mihaescu G, et al. Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy. Front Oncol. 2023; 13: 1273516.

[26] Manzo-Merino J, Thomas M, Fuentes-Gonzalez AM, Lizano M, Banks L. HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers. Expert Opin Ther Tar. 2013; 17(11): 1357-1368.

[27] Aarthy M, Singh SK. Interpretations on the interaction between protein tyrosine phosphatase and E7 oncoproteins of high and low-risk HPV: a computational perception. Acs Omega. 2021; 6(25): 16472-16487.

[28] Hasan UA, Zannetti C, Parroche P, et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med. 2013; 210(7): 1369-1387.

[29] Wang H, Zhao Q, Zhang Y, et al. Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Front Immunol. 2021; 12: 652054.

[30] Gottgens EL, Ostheimer C, Span PN, Bussink J, Hammond EM. HPV, hypoxia and radiation response in head and neck cancer. Brit J Radiol. 2018; 92(1093): 20180047.

[31] Stephen JK, Divine G, Chen KM, et al. Significance of p16 in site-specific HPV positive and HPV negative HNSCC. Cancer Clin Oncol. 2012; 2(1): 51-61.

[32] Adams A, Wise-Draper T, Wells S. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers. 2014; 6(3): 1793-1820.

[33] Gutierrez-Xicotencatl L, Pedroza-Saavedra A, Chihu-Amparan L, et al. Cellular functions of HPV16 E5 oncoprotein during oncogenic transformation. Mol Cancer Res. 2021; 19(2): 167-179.

[34] Tabatabaeian H, Bai Y, Huang R, Chaurasia A, Darido C. Navigating therapeutic strategies: hPV classification in head and neck cancer. Brit J Cancer. 2024; 131(2): 220-230.

[35] Al-Thawadi H, Gupta I, Jabeen A, et al. Co-presence of human papillomaviruses and Epstein-Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell Int. 2020; 20(1): 361.

[36] Strycharz-Dudziak M, Foltyn S, Dworzanski J, et al. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) in oropharyngeal cancer associated with EBV and HPV coinfection. Viruses-Basel. 2020; 12(9): 1008.

[37] Niya MHK, Tameshkel FS, Keyvani H, et al. Epstein-Barr virus molecular epidemiology and variants identification in head and neck squamous cell carcinoma. Eur J Cancer Prev. 2020; 29(6): 523-530.

[38] Yi M, Cai J, Li J, et al. Rediscovery of NF-κB signaling in nasopharyngeal carcinoma: how genetic defects of NF-κB pathway interplay with EBV in driving oncogenesis? J Cell Physiol. 2018; 233(8): 5537-5549.

[39] Rahman R, Shaikh MH, Gopinath D, Idris A, Johnson NW. Human papillomavirus and Epstein-Barr virus co-infection in oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Mol Oral Microbiol. 2023; 38(4): 259-274.

[40] Deng Z, Uehara T, Maeda H, Hasegawa M, Matayoshi S, Kiyuna A, et al. Epstein-Barr Virus and Human Papillomavirus Infections and Genotype Distribution in Head and Neck Cancers. PLOS ONE. 2014; 9(11): e113702.

[41] Blanco R, Carrillo-Beltran D, Corvalan AH, Aguayo F. High-risk human papillomavirus and Epstein-Barr virus coinfection: a potential role in head and neck carcinogenesis. Biology-Basel. 2021; 10(12): 1232.

[42] Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vacc Immunother. 2016; 12(6): 1418-1429.

[43] Nulton TJ, Olex AL, Dozmorov M, Morgan IM, Windle B. Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma. Oncotarget. 2017; 8(11): 17684-17699.

[44] Marquard FE, Jucker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2020; 172: 113729.

[45] Lee MJ, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res. 2020; 1867(6): 118679.

[46] Simpson DR, Mell LK, Cohen EEW. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015; 51(4): 291-298.

[47] Borges GA, Elias ST, Amorim B, et al. Curcumin downregulates thePI3K-AKT-mTORpathway and inhibits growth and progression in head and neck cancer cells. Phytother Res. 2020; 34(12): 3311-3324.

[48] Harsha C, Banik K, Ang HL, et al. Targeting AKT/mTOR in oral cancer: mechanisms and advances in clinical trials. Int J Mol Sci. 2020; 21(9): 3285.

[49] Nikitakis NG, Siavash H, Sauk JJ. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Tar. 2004; 4(8): 637-651.

[50] Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol. 2016; 56: 84-92.

[51] Rah B, Rather RA, Bhat GR, et al. JAK/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. Front Pharmacol. 2022; 13: 821344.

[52] Hu XY, Li J, Fu MR, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Tar. 2021; 6(1): 402.

[53] Guanizo AC, Fernando CD, Garama DJ, Gough DJ. STAT3: a multifaceted oncoprotein. Growth Factors. 2018; 36(1-2): 1-14.

[54] Jia LF, Wang YL, Wang CY. circFAT1 promotes cancer stemness and immune evasion by promoting STAT3 activation. Adv Sci. 2021; 8(13): 2003376.

[55] Sen M, Pollock NI, Black J, et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia. 2015; 17(3): 256-264.

[56] Meyer C, Pries R, Wollenberg B. Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC. Oral Oncol. 2011; 47(9): 818-826.

[57] Chen Z, Yan B, Van Waes C. Role of the NF-kappa B transcriptome and proteome as biomarkers in human head and neck squamous cell carcinomas. Biomark Med. 2008; 2(4): 409-426.

[58] Lun MY, Zhang PL, Pellitteri PK, et al. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappa B. Ann Clin Lab Sci. 2005; 35(3): 251-258. Sum.

[59] Greten F. The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer. Cancer Lett. 2004; 206(2): 193-199.

[60] Hartmann S, Bhola NE, Grandis JR. HGF/Met signaling in head and neck cancer: impact on the tumor microenvironment. Clin Cancer Res. 2016; 22(16): 4005-4013.

[61] Raj S, Kesari KK, Kumar A, et al. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022; 21(1): 31.

[62] Zhou G, Liu Z, Myers JN. TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem. 2016; 117(12): 2682-2692.

[63] Watling DL, Gown AM, Coltrera MD. Overexpression of P53 in head and neck-cancer. Head Neck-J Sci Spec. 1992; 14(6): 437-444.

[64] Doescher J, Piontek G, Wirth M, et al. Epstein-Barr virus infection is strictly associated with the metastatic spread of sinonasal squamous-cell carcinomas. Oral Oncol. 2015; 51(10): 929-934.

[65] Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023; 22(2): 127-144.

[66] Alsahafi E, Begg K, Amelio I, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019; 10: 540.

[67] Wang Z, Wang Q, Tao Y, et al. Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer. Sci Data. 2023; 10(1): 694.

[68] Lechien JR, Descamps G, Seminerio I, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers (Basel). 2020; 12(5): 1060.

[69] Liu S, Wang R, Fang J. Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. Discov Oncol. 2024; 15(1): 22.

[70] Fu E, Liu T, Yu S, et al. M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF. Oncol Rep. 2020; 44(2): 698-710.

[71] Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9): 582-598.

[72] Li X, González-Maroto C, Tavassoli M. Crosstalk between CAFs and tumour cells in head and neck cancer. Cell Death Discov. 2024; 10(1): 303.

[73] Quah HS, Cao EY, Suteja L, et al. Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. Nat Commun. 2023; 14(1): 1680.

[74] Gong XJ, Xiong JW, Gong Y, et al. Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC. Front Immunol. 2023; 14: 1275270.

[75] Kumar D, Kandl C, Hamilton CD, et al. Mitigation of tumor-associated fibroblast-facilitated head and neck cancer progression with anti-hepatocyte growth factor antibody ficlatuzumab. Jama Otolaryngol. 2015; 141(12): 1133-1139.

[76] Kumar D, New J, Vishwakarma V, et al. Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in head and neck squamous cell carcinoma progression. Cancer Res. 2018; 78(14): 3769-3782.

[77] Nishikoba N, Kumagai K, Kanmura S, et al. HGF-MET signaling shifts M1 macrophages toward an M2-like phenotype through PI3K-mediated induction of arginase-1 expression. Front Immunol. 2020; 11: 2135.

[78] Zhai YJ, Moosavi R, Chen MN. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases. Front Immunol. 2021; 12: 645699.

[79] Montler R, Bell RB, Thalhofer C, et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunol. 2016; 5(4): e70.

[80] Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015; 33(29). 3293-+.

[81] Wang C, Li Y, Jia L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021; 28(9): 1597-1613.

[82] Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. P Natl Acad Sci USA. 2007; 104(3): 973-978.

[83] Kavitha L, Priyadharsini JV, Kattula D, et al. Expression of CD44 in head and neck squamous cell carcinoma-an in-silico study. Glob Med Genet. 2023; 10(03): 221-228.

[84] Byun JY, Huang K, Lee JS, et al. Targeting HIF-1 alpha/NOTCH1 pathway eliminates CD44(+) cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma. Oncogene. 2022; 41(9): 1352-1363.

[85] Lee Y, Shin JH, Longmire M, et al. CD44(+) cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 2016; 22(14): 3571-3581.

[86] Shokouhifar A, Firouzi J, Nouri M, Sarab GA, Ebrahimi M. NK cell upraise in the dark world of cancer stem cells. Cancer Cell Int. 2021; 21(1): 682.

[87] Luo X, Qiu Y, Fitzsimonds ZR, et al. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway. Oncogene. 2024; 43(6): 388-394.

[88] Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021; 20(7): 531-550.

[89] Le J. Histone modifications: targeting head and neck cancer stem cells. World J Stem Cells. 2014; 6(5): 511-525.

[90] Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996; 56(11): 2488-2492.

[91] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1): 92.

[92] Moisan A, Lee YK, Zhang JD, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015; 17(1): 57-67. Research Support, N.I.H., Extramural.

[93] Nichols AC, Palma DA, Chow W, et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2013; 139(6): 617-622.

[94] Cochicho D, Esteves S, Rito M, et al. PIK3CA gene mutations in HNSCC: systematic review and correlations with HPV status and patient survival. Cancers. 2022; 14(5): 1286.

[95] Chang AS, Wang Y, Guo XP, et al. Identification of immune-related genes in the prognosis of head and neck cancer using a novel prognostic signature model. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023; 136(4): 478-489.

[96] Cui L, Lu Y, Zheng J, Guo B, Zhao X. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK. J Exp Clin Cancer Res. 2023; 42(1): 335.

[97] Xu T, Yang Y, Chen Z, et al. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling. J Exp Clin Cancer Res. 2023; 42(1): 190.

[98] Guan J, Xu X, Qiu G, et al. Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC. J Exp Clin Cancer Res. 2023; 42(1): 162.

[99] Mann JE, Kulkarni A, Birkeland AC, et al. The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel. Head Neck J Sci Spec. 2019; 41(9): 3114-3124.

[100] Gazdzicka J, Golabek K, Strzelczyk JK, Ostrowska Z. Epigenetic modifications in head and neck cancer. Biochem Genet. 2020; 58(2): 213-244.

[101] Danstrup CS, Marcussen M, Pedersen IS, et al. DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review. PLoS One. 2020; 15(12): e0244101.

[102] Hier J, Vachon O, Bernstein A, et al. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy. Sci Rep. 2021; 11(1): 10012.

[103] Zhou CC, Ye M, Ni SM, et al. DNA methylation biomarkers for head and neck squamous cell carcinoma. Epigenetics. 2018; 13(4): 398-409.

[104] Romanowska K, Sobecka A, Rawluszko-Wieczorek AA, Suchorska WM, Golusinski W. Head and neck squamous cell carcinoma: epigenetic landscape. Diagnostics. 2021; 11(1): 34.

[105] Castilho RM, Squarize CH, Almeida LO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 2017; 18(7): 1506.

[106] Laytragoon-Lewin N, Rutqvist LE, Lewin F. DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: new diagnostic approaches and treatment. Med Oncol. 2013; 30(3): 654.

[107] Pan YH, Song YD, Cheng LX, Xu HD, Liu J. Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma. J Cell Biochem. 2019; 120(12): 19482-19495.

[108] Weeramange CE, Tang KD, Vasani S, et al. DNA methylation changes in human papillomavirus-driven head and neck cancers. Cells. 2020; 9(6): 1359.

[109] Ekanayake Weeramange C, Tang KD, Irwin D, et al. Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer. Carcinogenesis. 2024; 45(3): 140-148.

[110] Li Y, Goldberg EM, Chen X, et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell. 2022; 82(20): 3901.

[111] Chen F, Qi S, Zhang X, et al. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/β-catenin pathway in oral squamous cell carcinoma. Int J Oncol. 2019; 54(4): 1183-1194.

[112] Ma H, Chang H, Yang W, et al. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma. Mol Cancer. 2020; 19(1): 4.

[113] Yeo-Teh N, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018; 19(6): 1706.

[114] Li T, Qin Y, Zhen Z, et al. Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma. Cell Prolif. 2019; 52(5): e12651.

[115] Bhattacharjee B, Syeda AF, Rynjah D, et al. Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment. Front Pharmacol. 2023; 14: 1174330.

[116] Jayaseelan VP, Arumugam P. Exosomal microRNAs targeting TP53 gene as promising prognostic markers for head and neck squamous cell carcinoma. Global Med Genet. 2022; 9(4): 277-286.

[117] Thomaidou AC, Batsaki P, Adamaki M, et al. Promising biomarkers in head and neck cancer: the most clinically important miRNAs. Int J Mol Sci. 2022; 23(15): 8257.

[118] Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck. 2009; 31(5): 642-654.

[119] Romanowska K, Sobecka A, Rawłuszko-Wieczorek AA, Suchorska WM, Golusiński W. Head and neck squamous cell carcinoma: epigenetic landscape. Diagnostics (Basel, Switzerland). 2020; 11(1): 34.

[120] Kanno Y, Chen CY, Lee HL, Chiou JF, Chen YJ. Molecular mechanisms of chemotherapy resistance in head and neck cancers. Front Oncol. 2021; 11: 640392.

[121] El-Mahdy HA, Mohamadin AM, Abulsoud AI, et al. miRNAs as potential game-changers in head and neck cancer: future clinical and medicinal uses. Pathol Res Pract. 2023; 245: 154457.

[122] Zou HH, Wei Z, Xu WG, et al. RHCG-upregulating polymeric nanoparticles for sensitized chemotherapy and immunotherapy in head and neck squamous cell carcinoma. Acs Appl Nano Mater. 2023; 6(14): 12764-12774.

[123] Vienne A, Collet L, Chevalier T, et al. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (& GE; 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study. BMC Cancer. 2023; 23(1): 663.

[124] Li MM, Sun DY, Song N, et al. Mutant p53 in head and neck squamous cell carcinoma: molecular mechanism of gain-of-function and targeting therapy (Review). Oncol Rep. 2023; 50(3): 162.

[125] Bhat AA, Yousuf P, Wani NA, et al. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy (vol 6, 12, 2021). Signal Transduct Tar Ther. 2021; 6(1): 93.

[126] Mao L, Xiao Y, Yang QC, et al. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. Oral Oncol. 2021; 121: 105472.

[127] Xing DT, Khor R, Gan H, et al. Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists. Cancers. 2021; 13(22): 5716.

[128] Dietrich D. FGFR-targeted therapy in head and neck carcinomas. HNO. 2021; 69(3): 172-184.

[129] Chen L, Mo DC, Hu M, et al. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. Int Immunopharmacol. 2023; 119: 110270.

[130] Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumor Biol. 2012; 33(3): 707-721.

[131] Atri S, Nasoohi N, Hodjat M. Azacitidine, as a DNMT inhibitor decreases hTERT gene expression and telomerase activity more effective compared with HDAC inhibitor in human head and neck squamous cell carcinoma cell lines. Curr Mol Pharmacol. 2021; 14(1): 60-67.

[132] Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). Oncol Lett. 2018; 15(5): 7497-7505.

[133] Devaraja K. Current prospects of molecular therapeutics in head and neck squamous cell carcinoma. Pharm Med. 2019; 33(4): 269-289.

[134] Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev. 2014; 40(4): 567-577.

[135] Yadav A, Goyal P, Agrawal CR, et al. Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India. Indian J Cancer. 2020; 57(1): 76-83.

[136] Temam S, Spicer J, Farzaneh F, et al. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. Ann Oncol. 2017; 28(11): 2827-2835.

[137] Tang XX, He J, Li B, et al. Efficacy and Safety of gefitinib in patients with advanced head and neck squamous cell carcinoma: a meta-analysis of randomized controlled trials. J Oncol. 2019; 2019: 6273438.

[138] Healthyni C, Subroto T, Megantara S, Jiranusornkul S, Levita J. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review). World Acad Sci J. 2022; 4(5).

[139] Liu XF, Suo HY, Zhou SL, et al. Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells. Cell Death Dis. 2021; 12(8): 728.

[140] Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol. 2005; 17(3): 212-217.

[141] Micaily I, Johnson J, Argiris A. An update on angiogenesis targeting in head and neck squamous cell carcinoma. Cancers Head Neck. 2020; 5(1): 5.

[142] Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest oncology group study S0420. J Clin Oncol. 2010; 28(20): 3330-3335.

[143] Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther. 2011; 10(7): 1241-1251.

[144] Liu J, Lin WP, Su W, et al. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC. Int Immunopharmacol. 2023; 119: 110243.

[145] Desilets A, Pfister DG, Wong W, et al. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. J Clin Oncol. 2023; 41(16): 106861.

[146] Saba NF, Steuer CE, Ekpenyong A, et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med. 2023; 29(4): 880-887.

[147] Bauman JE, Saba NF, Roe D, et al. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2021; 39(15).

[148] Bauman JE, Ohr J, Gooding WE, et al. Phase I study of ficlatuzumab and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer. Cancers. 2020; 12(6): 1537.

[149] Desilets A, Soulières D. PI3K inhibition for squamous cell head and neck carcinoma. Cancer J. 2022; 28(5): 369-376.

[150] Smith AE, Chan SC, Wang ZY, et al. Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in—and-dysregulated HNSCC via convergent iNHIBItion of mTOR activity. Cancer Res. 2023; 83(19): 3252-3263.

[151] Marret G, Isambert N, Rezai K, et al. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Invest New Drug. 2021; 39(6): 1641-1648.

[152] Geiger JL, Bauman JE, Gibson MK, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck J Sci Spec. 2016; 38(12): 1759-1764.

[153] Massarelli E, Lin H, Ginsberg LE, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015; 26(7): 1476-1480.

[154] Evrard D, Dumont C, Gatineau M, et al. Targeting the tumor microenvironment through mTOR inhibition and chemotherapy as induction therapy for locally advanced head and neck squamous cell carcinoma: the CAPRA study. Cancers. 2022; 14(18): 4509.

[155] Bauman JE, Arias-Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013; 49(5): 461-467.

[156] Ekshyyan O, Mills GM, Lian T, et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck J Sci Spec. 2010; 32(12): 1619-1628.

[157] Munster P, Mita M, Mahipal A, et al. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy. Cancer Manag Res. 2019; 11: 10463-10476.

[158] Chen TH, Chang PMH, Yang MH. Novel immune-modulating drugs for advanced head and neck cancer. Head Neck J Sci Spec. 2019; 41: 46-56.

[159] Yang ZJ, Liao JP, Cullen KJ, Dan HC. Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma. Cell Death Discov. 2020; 6(1).

[160] Li ZP, Liao JP, Yang ZJ, et al. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. Brit J Cancer. 2019; 120(3): 306-316.

[161] Du Y, Peyser ND, Grandis JR. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Therapeut. 2014; 142(1): 88-98.

[162] Caicedo-Granados E, Lin R, Fujisawa C, et al. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncol. 2014; 50(12): 1149-1156.

[163] Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015; 21(3): 526-533.

[164] Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. HER2 and HER3 as therapeutic targets in head and neck cancer. Cancer J. 2022; 28(5): 339-345.

[165] Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: from the bench to the bedside. J Exp Clin Canc Res. 2022; 41(1): 310.

[166] Forster MD, Dillon MT, Kocsis J, et al. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer. 2019; 123: 36-47.

[167] Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015; 33(29): 3293-3304.

[168] Bauml JM, Cohen RB, Aggarwal C. Immunotherapy for head and neck cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016; 8(3): 168-175.

[169] Okada T, Matsuki T, Fushimi C, et al. Nivolumab for platinum-refractory and -sensitive recurrent and metastatic head and neck squamous cell carcinoma. Anticancer Res. 2022; 42(10): 4907-4912.

[170] Moskovitz J, Moy J, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep. 2018; 20(2).

[171] Vasiliadou I, Breik O, Baker H, et al. Safety and treatment outcomes of nivolumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: retrospective multicenter cohort study. Cancers. 2021; 13(6): 1413.

[172] Yamashita G, Okamoto I, Ito T, et al. Efficacy of nivolumab and pembrolizumab in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Anticancer Res. 2023; 43(8): 3679-3683.

[173] Saleh K, Eid R, Haddad FGH, Khalife-Saleh N, HR Kourie. New developments in the management of head and neck cancer—impact of pembrolizumab. Ther Clin Risk Manag. 2018; 14: 295-303.

[174] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212): 1915-1928.

[175] Yu CH, Li Q, Zhang Y, et al. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022; 10: 941750.

[176] Alfieri S, Cavalieri S, Licitra L. Immunotherapy for recurrent/metastatic head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2018; 26(2): 152-156.

[177] Paderno A, Petrelli F, Lorini L, et al. The predictive role of PD-L1 in head and neck cancer: a systematic review and meta-analysis. Oral Oncol. 2024; 153: 106799.

[178] Wang S, Wu ZZ, Zhu SW, Wan SC, Zhang MJ, Zhang BX, et al. CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma. Mol Ther. 2023; 31(7): 2154-2168.

[179] Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol: Mechanisms of Disease. 2021; 16(1): 223-249.

[180] Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol. 2023; 41(12): 2166.

[181] Hu CM, Liu M, Li YT, et al. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. Front Immunol. 2023; 14: 1213716.

[182] Wang H-Q, Fu R, Man Q-W, et al. Advances in CAR-T cell therapy in head and neck squamous cell carcinoma. J Clin Med. 2023; 12(6): 2173.

[183] Wang XW, Shen YH, Wan XX, et al. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. J Transl Med. 2023; 21(1): 500.

[184] Mansfield D, Pencavel T, Kyula JN, et al. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncol. 2013; 49(2): 108-118.

[185] Letafati A, Ardekani OS, Naderisemiromi M, et al. Oncolytic viruses against cancer, promising or delusion? Med Oncol. 2023; 40(8): 246.

[186] Liang M. Clinical development of oncolytic viruses in china. Curr Pharm Biotechnol. 2012; 13(9): 1852-1857.

[187] Meliante PG, Petrella C, Fiore M, Minni A, Barbato C. Head and neck squamous cell carcinoma vaccine: current landscape and perspectives. Curr Issues Mol Biol. 2023; 45(11): 9215-9233.

[188] Ding ZY, Li Q, Zhang R, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021; 6(1).

[189] Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014; 20(9): 2433-2444.

[190] Xu JB, Liu H, Wang T, et al. CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy. Adv Sci. 2023; 10(17): e2207017.

[191] Muzaffar J, Kirtane K, Redman R, et al. Abstract CT226: phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor. Cancer Res. 2024; 84: CT226-CT226. 7_Supplement.

[192] Chen Y, Shi H-S, Hu Y, et al. Abstract 4108: safety and feasibility of personalized neoantigen DC vaccines in postoperative esophagus squamous cell carcinoma: a Phase 1b trial. Cancer Res. 2024; 84: 4108-4108. 6_Supplement.

[193] Lauterbach H, Schmidt S, Katchar K, et al. Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform. Front Oncol. 2021; 11: 732166.

[194] Guo X, Xu L, Nie L, et al. B cells in head and neck squamous cell carcinoma: current opinion and novel therapy. Cancer Cell Int. 2024; 24(1): 41.

[195] Li L, Huang JL, Liu QC, et al. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J Gastroenterol. 2004; 10(13): 1867-1871.

[196] Xu F, Li S, Li XL, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther. 2009; 16(9): 723-730.

[197] Chen S, Zhang Y, Fan Z, et al. [The initial observation of adenovirus vector-mediated herpes simplex virus-thymidine kinase gene/ganciclovir system and photodynamic therapy for oral malignant tumor treatments]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2011: 617. 29 6:610-3.

[198] Dehari H, Ito Y, Nakamura T, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003; 10(1): 75-85.

[199] Dharavath B, Butle A, Chaudhary A, et al. Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications. NPJ Precis Oncol. 2024; 8(1): 63.

[200] Biktasova A, Hajek M, Sewell A, et al. Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer. Clin Cancer Res. 2017; 23(23): 7276-7287.

[201] Viet CT, Dang D, Achdjian S, et al. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLoS One. 2014; 9(11): e112880.

[202] Burkitt K, Saloura V. Epigenetic modifiers as novel therapeutic targets and a systematic review of clinical studies investigating epigenetic inhibitors in head and neck cancer. Cancers. 2021; 13(20).

[203] Haigentz M Jr, Kim M, Sarta C, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012; 48(12): 1281-1288.

[204] Teknos TN, Grecula J, Agrawal A, et al. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest New Drugs. 2019; 37(4): 702-710.

[205] Okuyama K, Naruse T, Yanamoto S. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2023; 42(1): 114.

[206] Bann DV, Deschler DG, Goyal N. Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. Cancers. 2016; 8(10): 87.

[207] Chen F, Tang C, Yang F, et al. HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer. Sci Adv. 2024; 10(8): eadk3663.

[208] Li J, Ran H, Zeng X, et al. Identification of HOXB9 based on comprehensive bioinformatics analysis for predicting prognosis of head and neck squamous cell carcinoma. Medicine (Baltimore). 2023; 102(35): e35035.

[209] Li ZR, Wang Q, Huang XF, et al. Multi-omics analysis reveals that ferroptosis-related gene CISD2 is a prognostic biomarker of head and neck squamous cell carcinoma. J Gene Med. 2023; 26(1): e3580.

[210] Cierpikowski P, Leszczyszyn A, Bar J. The role of hedgehog signaling pathway in head and neck squamous cell carcinoma. Cells. 2023; 12(16).

[211] Liu XY, Zeng LL, Wang WL, et al. Integrated analysis of high-throughput sequencing reveals the regulatory potential of hsa_circ_0035431 in HNSCC. Oncol Lett. 2023; 26(4): 435.

[212] Zhang MJ, Liu J, Wan SC, et al. CSRP2 promotes cell stemness in head and neck squamous cell carcinoma. Head Neck J Sci Spec. 2023; 45(9): 2161-2172.

[213] Zhang CY, Xie LS, Lin Z. Homeobox-D 1 and FTO form a transcriptional-epigenetic feedback loop to promote head and neck cancer proliferation. Cell Biol Int. 2023; 47(12): 1987-1998.

[214] Yu S, Ma Z, Chen T, et al. ETV5 facilitates tumor progression in head-neck squamous cell carcinoma. Oral Dis. 2023; 30(4): 2004-2017.

[215] Kumai T, Shinomiya H, Shibata H, et al. Translational research in head and neck cancer: molecular and immunological updates. Auris Nasus Larynx. 2023; 51(2): 391-400.

[216] Zhang M, Hoyle RG, Ma ZK, et al. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Mol Ther. 2021; 29(8): 2583-2600.

[217] Wang DS, Lu Y, Nannapaneni S, et al. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. Oral Oncol. 2021; 112: 105074.

[218] Chai AWY, Yee PS, Cheong SC. Rational combinations of targeted therapy and immune checkpoint inhibitors in head and neck cancers. Front Oncol. 2022; 12: 837835.

[219] Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019; 16(10): 601-620.

[220] Zhou X, Wang X. Radioimmunotherapy in HPV-associated head and neck squamous cell carcinoma. Biomedicines. 2022; 10(8): 1990.

[221] Li KY, Zhou YJ, Zang ML, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024; 14: 1354543.

[222] Bruce J, Burr A, Kimple R, et al. Safety and toxicity of iopofosine I-131 with external beam radiation therapy (EBRT) in recurrent or metastatic head and neck cancer (HNC): results of a phase 1 study. Int J Radiat Oncol Biol Phys. 2024; 118(5): e36-e37.

[223] He Q, Gao H, Tan DJ, Zhang H, Wang JZ. mRNA cancer vaccines: advances, trends and challenges. Acta Pharm Sin B. 2022; 12(7): 2969-2989.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.